VRPX Overview

Trading Halt: Virpax Pharmaceuticals (VRPX) Inc has had its trading halted pending news.

Recent Developments: The company recently announced a 1-for-25 reverse stock split and received positive results from a dose range study for its product Probudur.

Five Below Financial Performance: Five Below, Inc. shares surged 11.9% in pre-market trading after reporting fourth-quarter earnings of $3.48 per share, exceeding estimates, and sales of $1.391 billion, slightly above expectations.

Market Movements: Several stocks experienced significant pre-market movements, with SAG Holdings rising 77.8% and ProAssurance Corporation gaining 50.6% due to acquisition announcements, while Zoomcar Holdings fell 28.4% following a reverse stock split.

Market Response to Federal Reserve Announcement: U.S. stock futures rose following the Federal Reserve's decision to maintain interest rates, with Chairman Jerome Powell stating that inflation from tariffs would be "transitory." The S&P 500 and other indices saw gains, while analysts noted concerns about stagflation despite a broad rally in sectors like energy and technology.

Economic Insights and Stock Performance: Analysts suggest that recent market volatility presents a buying opportunity, emphasizing strong labor market fundamentals and consumer spending as mitigating factors against recession risks. Notable stock movements included Boeing's significant rise due to delivery improvements and Nvidia's rebound after its CEO's address.

StoneCo Ltd Earnings Report: StoneCo Ltd shares rose 8% in pre-market trading after reporting better-than-expected fourth-quarter earnings and sales results.

Stock Movements: Several stocks saw significant pre-market movements, with Leishen Energy gaining 90%, while FST Corp fell 23% following a previous surge.

Reverse Stock Split Announcement: Virpax Pharmaceuticals will implement a 1-for-25 reverse stock split of its common stock to comply with the minimum bid price rule.

Additional Information: The announcement includes references to Seeking Alpha’s Quant Rating and historical earnings data for the company.

Harrow, Inc. Stock Surge: Harrow, Inc. shares rose 23.1% in pre-market trading after announcing its fourth quarter and year-end 2024 financial results along with 2025 revenue guidance.

Pre-Market Trading Movements: Several stocks experienced significant changes in pre-market trading, with Regencell Bioscience Holdings gaining 45.7% and Avenue Therapeutics falling 40.3%.